6-methoxy-2-(pyrimidin-2-yl)nicotinic acid | 1607429-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-methoxy-2-(pyrimidin-2-yl)nicotinic acid
• 英文别名: 6-Methoxy-2-(2-pyrimidinyl)-3-pyridinecarboxylic acid；6-methoxy-2-pyrimidin-2-ylpyridine-3-carboxylic acid
• CAS: 1607429-55-9
• 化学式: C₁₁H₉N₃O₃
• 分子量: 231.211
• InChiKey: ATAHWRKJOFGEQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  85.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 2-(((3R,6R)-6-methylpiperidin-3-yl)oxy)isonicotinate 、 6-methoxy-2-(pyrimidin-2-yl)nicotinic acid 在 1-丙基磷酸酐 、 三乙胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 2-({(3R,6R)-1-[(6-methoxy-2-pyrimidin-2-ylpyridin-3-yl)carbonyl]-6-methylpiperidin-3-yl}oxy)pyridine-4-carboxylate
  参考文献：
  名称：

  [EN] 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS
  [FR] COMPOSÉS DE TYPE 2-PYRYDYLOXY-4-ESTER ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE

  摘要：

  本发明涉及2-吡啶氧基-4-酯类化合物，其为俄雷欣受体拮抗剂。本发明还涉及在俄雷欣受体参与的神经和精神障碍和疾病的潜在治疗或预防中使用本文所述的2-吡啶氧基-4-酯类化合物。本发明还涉及包含这些化合物的药物组合物。本发明还涉及在俄雷欣受体参与的这些疾病的预防或治疗中使用这些药物组合物。

  公开号：

  WO2014099696A1

文献信息

• 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS
  申请人：KUDUK Scott D.

  公开号：US20160214960A1

  公开（公告）日：2016-07-28

  The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-4-酯化合物，其是睡眠荷尔蒙受体拮抗剂。本发明还涉及使用此处所述的2-吡啶氧基-4-酯化合物在潜在的涉及睡眠荷尔蒙受体的神经和精神障碍和疾病的治疗或预防中。本发明还涉及包含这些化合物的药物组合物。本发明还涉及使用这些药物组合物在预防或治疗涉及睡眠荷尔蒙受体的这些疾病中。
• HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160068514A1

  公开（公告）日：2016-03-10

  The present invention is directed to halo and trifluoromethyl substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及卤代和三氟甲基取代化合物，其为促进素受体拮抗剂。本发明还涉及所述化合物在潜在的神经系统和精神疾病的治疗或预防中的用途，其中促进素受体参与其中。本发明还涉及包含这些化合物的制药组合物。本发明还涉及这些制药组合物在预防或治疗促进素受体参与的这些疾病中的用途。
• US9556145B2
  申请人：——

  公开号：US9556145B2

  公开（公告）日：2017-01-31
• [EN] 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE TYPE 2-PYRYDYLOXY-4-ESTER ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014099696A1

  公开（公告）日：2014-06-26

  The present invention is directed to 2-pyridyloxy-4-ester compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ester compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及2-吡啶氧基-4-酯类化合物，其为俄雷欣受体拮抗剂。本发明还涉及在俄雷欣受体参与的神经和精神障碍和疾病的潜在治疗或预防中使用本文所述的2-吡啶氧基-4-酯类化合物。本发明还涉及包含这些化合物的药物组合物。本发明还涉及在俄雷欣受体参与的这些疾病的预防或治疗中使用这些药物组合物。